BETA This is a beta service - your feedback will help us improve it.


Emmaus Life Sciences opens in Dubai

Accelerates MENA growth strategy


U.S.-based Emmaus Life Sciences, Inc. a leader in sickle cell disease treatment, has opened its regional office in Dubai. The Dubai office will be utilized to enhance Emmaus’ relationships with clinicians and patient groups at major hospitals and other government-sponsored healthcare facilities in communities throughout the Middle East and North Africa (MENA) region.

These partnerships are intended to accelerate Emmaus’ path to registration and commercialization of Endari and to ensure that the estimated 100,000 potentially treatable sickle cell disease patients in the MENA region have access to the product information and real-time assistance needed to effectively treat their disease.

The opening of its Dubai office is an important step in Emmaus’ overall strategy for the MENA region, which will include the following:

  • Initially target the six Gulf Cooperation Council (GCC) countries of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE) for the commercialization of Endari and partner with local distributors.
  • Leverage the regulatory resources of the local distributors to facilitate product registration and marketing authorization and to manage the delivery of Endari to customers as well as payment processing.
  • As product registration and marketing authorization are obtained, deploy local medical science liaisons (MSLs) and account managers to call on local hospitals and clinics.
  • Beginning in 2021, expand within the rest of the MENA region.

Dubai is expected to become the main point of contact for clinicians and hospitals across the MENA region in the treatment of sickle cell disease patients.